Five things for pharma marketers to know: Monday, May 2, 2016
Steve Miller, chief medical officer, Express Scripts
1. Express Scripts plans to respond to price hikes on old drugs through a new program. The pharmacy benefit manager said the “market events” program will be optional for its clients and is largely a response to high-profile increases made by Valeant Pharmaceuticals and Turing Pharmaceuticals. (Bloomberg)
2. The FDA approved the first drug to treat hallucinations and delusions stemming from Parkinson's disease. The drug, Nuplazid (pimavanserin), manufactured by Acadia Pharmaceuticals, was granted Breakthrough Therapy Designation in 2014. Its commercial launch is planned for June.
3. Regeneron's late-stage trial for fasinumab, an experimental treatment for moderate-to severe plaque psoriasis, was successful, according to the drugmaker. Patients reported less pain compared to placebo after 16 weeks. (Reuters)
4. Novo Nordisk said its weekly GLP-1 agonist, NN9535, reduced cardiovascular risk when compared to placebo. The drugmaker said it will submit the drug to U.S. regulators at the end of 2016. (BioCentury)
5. Charlie Munger, vice chairman of Berkshire Hathaway, described Valeant Pharmaceuticals as a “sewer” that deserved the backlash. He added that the business model “was enormously flawed.” (Reuters)